ProPhase Labs, Inc. (PRPH)
NASDAQ: PRPH · Real-Time Price · USD
0.3865
+0.0365 (10.41%)
At close: Oct 24, 2025, 4:00 PM EDT
0.3973
+0.0108 (2.81%)
After-hours: Oct 24, 2025, 7:50 PM EDT
ProPhase Labs Revenue
ProPhase Labs had revenue of $1.25M in the quarter ending June 30, 2025, a decrease of -17.09%. This brings the company's revenue in the last twelve months to $5.59M, down -11.64% year-over-year. In the year 2024, ProPhase Labs had annual revenue of $6.77M, down -80.65%.
Revenue (ttm)
$5.59M
Revenue Growth
-11.64%
P/S Ratio
2.10
Revenue / Employee
$58,208
Employees
96
Market Cap
16.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.77M | -28.21M | -80.65% |
| Dec 31, 2023 | 34.98M | -87.66M | -71.48% |
| Dec 31, 2022 | 122.65M | 43.61M | 55.17% |
| Dec 31, 2021 | 79.04M | 64.53M | 444.59% |
| Dec 31, 2020 | 14.51M | 4.64M | 46.96% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PRPH News
- 2 days ago - ProPhase Labs to Present at the 2025 ThinkEquity Conference - GlobeNewsWire
- 4 days ago - ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology - GlobeNewsWire
- 4 weeks ago - PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CROWN MEDICAL COLLECTIONS $50 MILLION A/R INITIATIVE - GlobeNewsWire
- 4 weeks ago - ProPhase Continues its Exploration of a Crypto Treasury Strategy - GlobeNewsWire
- 6 weeks ago - ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor - GlobeNewsWire
- 7 weeks ago - ProPhase Labs Inc. to Participate in Renmark's Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025 - GlobeNewsWire
- 2 months ago - ProPhase Labs, Inc. (PRPH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders - GlobeNewsWire